var data={"title":"Hydrocortisone (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydrocortisone (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/389793?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydrocortisone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydrocortisone (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=hydrocortisone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydrocortisone (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116174\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>A-Hydrocort [DSC];</li>\n      <li>Cortef;</li>\n      <li>Solu-CORTEF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116175\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cortef;</li>\n      <li>Solu-Cortef</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116204\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Systemic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116314\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory or immunosuppressive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: Initial: 100 to 500 mg/dose at intervals of 2, 4, or 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 20 to 240 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis, acute exacerbations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note</b>: Treatment guidelines recommend the use of high-dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: 800 mg/day for 1 week, followed by 320 mg every other day for 1 month.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 200 mg/day for 1 week, followed by 80 mg every other day for 1 month.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adrenal insufficiency: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute adrenal insufficiency (adrenal crisis) (off-label dose): </i>100 mg IV bolus, immediately followed by 200 mg over 24 hours as a continuous IV infusion or in divided doses (IM or IV) every 6 hours, then 100 mg over 24 hours the following day (Allolio 2015; ES [Bornstein 2016]). Alternatively, may administer 100 mg IV bolus, then 50 to 75 mg IV every 6 hours for 24 hours, followed by a slow taper over the next 72 hours (administering doses every 4 to 6 hours during taper) (Gardner 2011). <b>Note:</b> Appropriate fluid resuscitation is also required (ES [Bornstein 2016]; Gardner 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic adrenal insufficiency (physiologic replacement) (off-label dose):</i> Oral: 15 to 25 mg daily in 2 to 3 divided doses. Administer the largest dose in the morning upon awakening, followed by next dose 2 hours after lunch (two-dose regimen) or next dose at lunch, followed by smallest dose in the afternoon no later than 4 to 6 hours before bedtime (three-dose regimen) (ES [Bornstein 2016]; ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Temporary adrenal insufficiency (temporary), physiologic replacement following resection of an ACTH-producing tumor or unilateral adrenalectomy (off-label dose):</i> Oral: 10 to 12 mg/m2/day in 2 to 3 divided doses, with the first dose taken as soon as possible after waking; continue hydrocortisone until HPA axis recovers, generally 6 to 12 months following resection of ACTH-producing tumors or 18 months following unilateral adrenalectomy (ES [Neiman 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital adrenal hyperplasia (off-label dose):</b> Oral: 15 to 25 mg/day in 2 to 3 divided doses (Speiser 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress dosing in patients known to be adrenally-suppressed (ie, prevention of adrenal crisis in glucocorticoid-treated patients) (off-label dose): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sickness:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Illness with fever:</i> Oral: Double the routine oral hydrocortisone dose until recovery for fever &gt;38&deg;C [100.4&deg;F] or triple the routine oral hydrocortisone dose until recovery for fever &gt;39&deg;C [102.2&deg;F]; return to standard dose within 1 to 2 days (Allolio 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gastroenteritis with vomiting and/or diarrhea:</i> IM, SubQ: 100 mg dose given early in course of illness; repeat after 6 to 12 hours (Allolio 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe infection (eg, pneumonia/with altered cognition):</i> IM, SubQ: 100 mg dose given early in course of illness; repeat after 6 to 12 hours until recovery (Allolio 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Surgery: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Minor stress (ie, inguinal herniorrhaphy):</i> IV: 25 mg/day for 1 day (Coursin 2002; Salem 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Moderate stress (ie, joint replacement, cholecystectomy):</i> IV: 50 to 75 mg/day (25 mg every 8 to 12 hours) for 1 to 2 days (Coursin 2002; Salem 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Major stress (pancreatoduodenectomy, esophagogastrectomy, cardiac surgery):</i> IV: 100 to 150 mg/day (50 mg every 8 to 12 hours) for 2 to 3 days (Coursin 2002; Salem 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic shock (off-label use):</b> IV: 200 mg/day as a continuous infusion (Rhodes 2017; Weber-Carstens 2007) <b>or</b> 50 mg IV bolus every 6 hours (Annane 2002; Sprung 2008). Taper slowly (over several days) when vasopressors are no longer required; do not stop abruptly. <b>Note:</b> Low-dose hydrocortisone in septic shock patients may cause a significant increase in hyperglycemia and hypernatremia. A small study demonstrated that repetitive bolus doses of hydrocortisone caused significant hyperglycemia that was not seen during continuous infusion (Weber-Carstens 2007); practice guidelines recommend strategies for avoidance and/or detection of these side effects (eg, the use of continuous infusion) (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid storm (off-label use):</b> IV: 300 mg loading dose, followed by 100 mg every 8 hours (ATA [Ross 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116312\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hydrocortisone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydrocortisone (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anti-inflammatory or immunosuppressive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants and Children:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.5 to 10 mg/kg/day <b>or</b> 75 to 300 mg/m<sup>2</sup>/day in divided doses every 6 to 8 hours (Kliegman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer labeling: Initial: 0.56 to 8 mg/kg/day or 20 to 240 mg/m<sup>2</sup>/day in 3 or 4 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: 1 to 5 mg/kg/day <b>or</b> 30 to 150 mg/m<sup>2</sup>/day divided every 12 to 24 hours (Kliegman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adolescents:</i> Oral, IM, IV, SubQ: 15 to 240 mg every 12 hours (Kliegman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital adrenal hyperplasia (off-label dose):</b> Oral: (tablets): Infants, Children, and Adolescents: <b>Note:</b> Administer morning dose as early as possible. Tablets may result in more reliable serum concentrations than oral liquid formulation; use of oral suspension is not recommended. Doses must be individualized by monitoring growth, bone age, and hormonal levels; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers (AAP 2000; AAP 2010; Endocrine Society [Speiser 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 10 to 15 mg/m<sup>2</sup>/day in 3 divided doses; higher initial doses (20 mg/m<sup>2</sup>/day) may be required to achieve initial target hormone serum concentrations (AAP 2010; Endocrine Society [Speiser 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: Usual requirement:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 2.5 to 5 mg/<b>dose</b> 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 5 to 10 mg/<b>dose</b> 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Physiologic replacement (off-label dose):</b> Infants and Children: Oral: 8 to 10 mg/m<sup>2</sup>/day divided every 8 hours; up to 12 mg/m<sup>2</sup>/day in some patients; to replicate diurnal variation, the highest doses are typically administered in the morning and mid-day dose with the lower dose in the evening (Ahmet 2011; Elder 2015; Gupta 2008; Maguire 2007; Shulman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic shock (off-label use): </b> Infants, Children, and Adolescents: IV: 50 to 100 mg/m<sup>2</sup>/day (Marx 2014; Shulman 2007); in some cases, doses may be titrated up to 50 mg/<b>kg</b>/day for shock reversal; however, efficacy data variable with the higher doses (Brierley 2009; Menon 2012). <b>Note:</b> Use recommended only in fluid refractory, catecholamine-resistant shock, and suspected or proven absolute (classic) adrenal insufficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116315\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897565\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897566\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116380\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">A-Hydrocort: 100 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solu-CORTEF: 100 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortef: 5 mg, 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116180\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116346\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food or milk to decrease GI upset.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: For IM or IV administration: Dermal and/or subdermal skin depression may occur at injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Avoid injection into deltoid muscle (high incidence of subcutaneous atrophy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV bolus: Administer undiluted over at least 30 seconds; for large  doses (&ge;500 mg), administer over 10 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV intermittent infusion: Further dilute in a compatible fluid and administer over 20 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116215\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergic states:</b> Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions, or acute noninfectious laryngeal edema (epinephrine is the drug of first choice).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatologic diseases:</b> Atopic dermatitis; bullous dermatitis herpetiformis; contact dermatitis; exfoliative dermatitis; exfoliative erythroderma; pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); severe psoriasis; severe seborrheic dermatitis; mycosis fungoides.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edematous states:</b> To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocrine disorders:</b> Acute adrenocortical insufficiency; congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis; primary or secondary adrenocortical insufficiency; preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GI diseases:</b> To tide the patient over a critical period of the disease in ulcerative colitis and regional enteritis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic disorders:</b> Acquired (autoimmune) hemolytic anemia; congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia); erythroblastopenia (RBC anemia); immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) in adults; pure red cell aplasia; select cases of secondary thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neoplastic diseases:</b> Palliative management of leukemias and lymphomas (adults); acute leukemia of childhood.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nervous system:</b> Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. <b>Note</b>: Treatment guidelines recommend the use of high-dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic diseases:</b> Severe acute and chronic allergic and inflammatory processes involving the eye, such as allergic conjunctivitis; allergic corneal marginal ulcers; anterior segment inflammation; chorioretinitis; diffuse posterior uveitis and choroiditis; herpes zoster ophthalmicus; iritis and iridocyclitis; keratitis; optic neuritis; sympathetic ophthalmia; other ocular inflammatory conditions unresponsive to topical corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory diseases:</b> Aspiration pneumonitis; bronchial asthma; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; idiopathic eosinophilic pneumonias; Loeffler syndrome (not manageable by other means); symptomatic sarcoidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatic disorders:</b> As adjunctive therapy for short-term administration in acute and subacute bursitis, acute gouty arthritis, acute nonspecific tenosynovitis, ankylosing spondylitis, epicondylitis, posttraumatic osteoarthritis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, synovitis of osteoarthritis; during an exacerbation or as maintenance therapy in acute rheumatic carditis, dermatomyositis (polymyositis), temporal arteritis, and systemic lupus erythematosus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Miscellaneous:</b> Trichinosis with neurologic or myocardial involvement; tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726023\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>In-hospital cardiac arrest; Septic shock; Thyroid storm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116164\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydroCHLOROthiazide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortef may be confused with Coreg, Lortab</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydroCHLOROthiazide)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solu-CORTEF may be confused with SOLU-Medrol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116246\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atheromatous embolism, bradycardia, cardiac arrhythmia, cardiac failure (especially in susceptible patients), cardiomegaly, circulatory shock, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post-myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Arachnoiditis (intrathecal administration), depression, emotional lability, euphoria, headache, increased intracranial pressure (with pseudotumor cerebri; usually following discontinuation), insomnia, malaise, meningitis (intrathecal administration), myasthenia, neuritis, neuropathy, paraplegia (intrathecal administration), paresthesia, personality changes, psychic disorder, seizure, sensory disturbance (intrathecal administration), tingling of skin (especially in the perineal area after IV injection), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, allergic dermatitis, alopecia, atrophic striae, burning sensation of skin (especially in the perineal area after IV injection), diaphoresis, ecchymosis, erythema (including facial), exfoliation of skin, hyperpigmentation, hypertrichosis, hypopigmentation, skin atrophy, skin rash, suppression of skin test reaction, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal suppression, Cushing syndrome, diabetes mellitus (latent), fluid retention, glycosuria, growth suppression, hirsutism, HPA-axis suppression, hypercalcemia (associated with cancers), hyperglycemia (including increased requirements for insulin or oral hypoglycemic agents in diabetes mellitus), hypokalemia, hypokalemic alkalosis, impaired glucose tolerance, lipodystrophy, lipomatosis (epidural), menstrual disease (menstrual irregularities), moon face, negative nitrogen balance, protein catabolism, sodium retention, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, carbohydrate intolerance, dyspepsia, gastrointestinal disease (intrathecal administration), gastrointestinal perforation (small and large intestine, particularly in patients with inflammatory bowel disease), hiccups, increased appetite, nausea, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Asthenospermia, bladder dysfunction (intrathecal administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis, petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly, increased serum transaminases (usually mild elevations and reversible on discontinuation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Increased susceptibility to infection, infection, sterile abscess</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Atrophy at injection site (cutaneous and subcutaneous), postinjection flare (intra-articular use), skin edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, Charcot-like arthropathy, lower extremity weakness (intrathecal administration), osteonecrosis (aseptic necrosis of femoral and humoral heads), osteoporosis, pathological fracture (long bones), rupture of tendon (particularly Achilles tendon), steroid myopathy, vertebral compression fracture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract (posterior subcapsular), exophthalmos, glaucoma, increased intraocular pressure, retinopathy (central serous chorioretinopathy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, blindness (periocular injection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116223\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hydrocortisone or any component of the formulation; systemic fungal infections; use in premature infants (formulations containing benzyl alcohol only); idiopathic thrombocytopenia purpura (IM administration only); intrathecal administration; live or live, attenuated virus vaccines (with immunosuppressive doses of corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116244\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropical climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with <i>Strongyloides</i> infections; hyperinfection, dissemination and fatalities have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression, or psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Oral steroid treatment is not recommended for the treatment of acute optic neuritis; may increase frequency of new episodes and does not affect short- or long-term visual outcomes. Use with caution in patients with ocular herpes simplex; corneal perforation may occur; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Pheochromocytoma crisis has been reported with corticosteroids (may be fatal). Consider the risk of pheochromocytoma crisis prior to administering corticosteroids in patients with suspected pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol and some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116271\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9144&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116218\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116219\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treating women with adrenal insufficiency (primary or central) during pregnancy, hydrocortisone is the preferred corticosteroid. Doses may need to be adjusted as pregnancy progresses, and stress doses may be required during active labor. Pregnant women with adrenal insufficiency should be monitored at least once each trimester (ES [Bornstein 2016]; ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2016). Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma (ACOG 2008; GINA 2016; Namazy 2016). Women who require systemic corticosteroids for management of their asthma should be given intravenous corticosteroids, such as hydrocortisone, during labor and for 24 hours after delivery to prevent adrenal crisis (ACOG 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (G&ouml;testam Skorpen 2016; Makol 2011; &Oslash;stensen 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116222\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids are present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfed infant (eg, growth suppression, interfere with endogenous corticosteroid production). Single doses of hydrocortisone are considered acceptable for use in breastfeeding females; data is not available following prolonged use (WHO 2002). Corticosteroids are generally considered acceptable in breastfeeding females when used in usual doses (G&ouml;testam Skorpen 2016; WHO 2002); however, monitoring of the infant is recommended (WHO 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfed infant (based on a study using prednisolone) (Bae 2012; Butler 2014; G&ouml;testam Skorpen 2016; Leachman 2006; Makol 2011; Ost 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116345\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B<sub>6</sub>, C, D, folate, calcium, zinc, phosphorus, and decreased sodium. Some products may contain sodium. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116350\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum glucose, electrolytes; blood pressure, weight, presence of infection; monitor IOP with therapy &gt;6 weeks; bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); growth in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116300\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Short-acting corticosteroid with minimal sodium-retaining potential; decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116303\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral:  96% &plusmn; 20% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 27 &plusmn; 7 L (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: IV: 92% &plusmn; 2% (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 2 &plusmn; 0.3 hours; Oral: 1.8 &plusmn; 0.5 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 1.2 &plusmn; 0.4 hours (Czock 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (Czock 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8116382\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Solu-CORTEF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $16.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $29.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $59.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (1): $119.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cortef Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $59.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $200.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $380.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hydrocortisone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $16.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $57.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $108.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961979\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actocortina (ES);</li>\n      <li>Aftasone (ES);</li>\n      <li>Arvisone (IN);</li>\n      <li>Biocort (PH);</li>\n      <li>Cipcorlin (IN);</li>\n      <li>Clovisone (PH);</li>\n      <li>Colifoam (AE, AT, AU, DE, DK, FI, GB, GR, IE, IT, MT, NZ, PT, SE);</li>\n      <li>Colofoam (FR);</li>\n      <li>Corhydron (PL);</li>\n      <li>Coripen (UY);</li>\n      <li>Cort-S (ET, IN, LK);</li>\n      <li>Cortaject (ZA);</li>\n      <li>Cortef (BB, BD, HR, HU, TH);</li>\n      <li>Cortifoam (IL);</li>\n      <li>Cortin (PH);</li>\n      <li>Cortis-100 (PH);</li>\n      <li>Cortisol (PK, UY);</li>\n      <li>Cortisol L.C.H. (CL);</li>\n      <li>Cortisona (BR);</li>\n      <li>Covocort (ZA);</li>\n      <li>Dhartisone-100 (ID);</li>\n      <li>Drosodin (MX);</li>\n      <li>Efcorlin (IN);</li>\n      <li>Entofoam (IN);</li>\n      <li>Fartison (ID);</li>\n      <li>Flebocortid (IT, MX);</li>\n      <li>Flemex (MX);</li>\n      <li>Fridalit (AR);</li>\n      <li>Harond (KR);</li>\n      <li>Hidrocort (VE);</li>\n      <li>Hidrocortif (EC);</li>\n      <li>Hidrotisona (AR);</li>\n      <li>Hison (BD);</li>\n      <li>Hycort (BD, PH);</li>\n      <li>Hycortil (PH);</li>\n      <li>Hydrocort (IL);</li>\n      <li>Hydrocortistab (CY);</li>\n      <li>Hydrosone (SA);</li>\n      <li>Hydrotopic (PH);</li>\n      <li>Hyson (TW);</li>\n      <li>Hysone (AU, KR);</li>\n      <li>Kortef (UA);</li>\n      <li>Lyo-Cortin (GR);</li>\n      <li>M-Cort (IN);</li>\n      <li>Nositrol (MX);</li>\n      <li>Oralsone (AR);</li>\n      <li>Plenadren (CZ, DE, DK, EE, ES, GB, HR, HU, IS, LT, LV, MT, NL, NO, PL, PT, SE, SK);</li>\n      <li>Primacor (LK);</li>\n      <li>Primacort (PE);</li>\n      <li>Rapicort (PT);</li>\n      <li>Rapison (JP, KR);</li>\n      <li>Rolak (GR);</li>\n      <li>Samcort (LK);</li>\n      <li>Saxizon (JP);</li>\n      <li>Solhidrol (MX);</li>\n      <li>Solu Cortef (AE, BD, BE, BH, BR, CH, CL, CO, CY, DK, EC, EE, EG, ET, FI, GB, GR, HK, HN, HR, HU, IE, IS, IT, JO, KR, KW, LB, LU, LV, MY, NL, NO, PE, PH, PK, PT, QA, RU, SA, SE, SG, TH, TR, TW, UA, ZA, ZW);</li>\n      <li>Solu-Cortef (AU, BB, CN, JP, MT, NZ, VE, VN);</li>\n      <li>Solu-Tisone (TW);</li>\n      <li>Stericort (PH);</li>\n      <li>Unicort (BD);</li>\n      <li>Zonac (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo; <i>JAMA</i>, 2002, 288(7):886-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12186608/pubmed\" target=\"_blank\" id=\"12186608\">12186608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahmet A, Kim H, and Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2011;7:13. doi: 10.1186/1710-1492-7-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/21867553/pubmed\" target=\"_blank\" id=\"21867553\">21867553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    A-Hydrocort (hydrocortisone injection) [prescribing information]. Lake Forest, IL: Hospira; October 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allolio B. Extensive expertise in endocrinology. Adrenal crisis. <i>Eur J Endocrinol</i>. 2015 Mar;172(3):R115-R24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/25288693/pubmed\" target=\"_blank\" id=\"25288693\">25288693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. <i>Pediatrics</i>. 2000;106(6):1511-1518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/11099616/pubmed\" target=\"_blank\" id=\"11099616\">11099616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Statement of endorsement: congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Pediatrics. 2010;126(5):1051. http://pediatrics.aappublications.org/cgi/content/extract/126/5/1051. Accessed May 10, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo; <i>JAMA</i>, 2002, 288(7):862-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12186604/pubmed\" target=\"_blank\" id=\"12186604\">12186604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arlt W and Allolio B, &ldquo;Adrenal Insufficiency,&rdquo; <i>Lancet</i>, 2003, 361(9372):1881-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12788587/pubmed\" target=\"_blank\" id=\"12788587\">12788587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beck RW, Cleary PA, Anderson MM Jr, et al, &ldquo;A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. The Optic Neuritis Study Group,&rdquo; <i>N Engl J Med</i>, 1992, 326(9):581-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/1734247/pubmed\" target=\"_blank\" id=\"1734247\">1734247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids,&rdquo; <i>J Neurotrauma</i>, 2007, 24(Suppl 1):91-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/17511554/pubmed\" target=\"_blank\" id=\"17511554\">17511554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo; <i>N Engl J Med</i>, 2003, 348(8):727-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12594318/pubmed\" target=\"_blank\" id=\"12594318\">12594318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortef (hydrocortisone tablets) [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo; <i>JAMA</i>, 2002, 287(2):236-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/11779267/pubmed\" target=\"_blank\" id=\"11779267\">11779267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czock D, Keller F, Rasche FM, H&auml;ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/15634032/pubmed\" target=\"_blank\" id=\"15634032\">15634032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo; <i>JAMA</i>, 2002, 288(22):2859-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12472328/pubmed\" target=\"_blank\" id=\"12472328\">12472328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards P, Arango M, Balica L, et al, &ldquo;Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury - Outcomes at 6 Months,&rdquo; <i>Lancet</i>, 2005, 365(9475):1957-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/15936423/pubmed\" target=\"_blank\" id=\"15936423\">15936423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elder CJ, Dimitri P. <i>Arch Dis Child Educ Pract Ed</i>. 2015;100(5):272-276. doi: 10.1136/archdischild-2014-307325.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/25561746/pubmed\" target=\"_blank\" id=\"25561746\">25561746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi: 10.1210/jc.2016-2118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/27736313/pubmed\" target=\"_blank\" id=\"27736313\">27736313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardner DG, Chapter 24. Endocrine Emergencies, Greenspan&rsquo;s Basic &amp; Clinical Endocrinology, 9ed. 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. Available at http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/26888948/pubmed\" target=\"_blank\" id=\"26888948\">26888948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta P and Bhatia V. Corticosteroid physiology and principles of therapy.<i> Indian J Pediatr</i>. 2008;75(10):1039-1044. doi: 10.1007/s12098-008-0208-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/19023528/pubmed\" target=\"_blank\" id=\"19023528\">19023528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hotchkiss RS and Karl IE, &ldquo;The Pathophysiology and Treatment of Sepsis,&rdquo; <i>N Engl J Med</i>, 2003, 348(2):138-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/12519925/pubmed\" target=\"_blank\" id=\"12519925\">12519925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF. <i>Nelson Textbook of Pediatrics</i>, 20th ed. Philadelphia, PA: Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maguire AM, Ambler GR, Moore B, et al. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. <i>Pediatrics</i>. 2007;120(1):e164-e171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/17576782/pubmed\" target=\"_blank\" id=\"17576782\">17576782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/18496365/pubmed\" target=\"_blank\" id=\"18496365\">18496365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo; <i>Arch Intern Med</i>, 2008, 168(10):1034-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/18504331/pubmed\" target=\"_blank\" id=\"18504331\">18504331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23860985\"></a>Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. <i>JAMA</i>. 2013;310(3):270-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/23860985/pubmed\" target=\"_blank\" id=\"23860985\">23860985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19139319\"></a>Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. <i>Arch Intern Me</i>d. 2009;169(1):15-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/19139319/pubmed\" target=\"_blank\" id=\"19139319\">19139319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE clinical guideline CG186. London, UK: National Institute for Health and Care Excellence; October 2014. https://www.nice.org.uk/guidance/cg186. Accessed October 21, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2015;132(suppl 2):S315-S367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/26472989/pubmed\" target=\"_blank\" id=\"26472989\">26472989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. <i>Anaesthesia</i>. 1998;53(11):1091-1104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/10023279/pubmed\" target=\"_blank\" id=\"10023279\">10023279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bjorkhem I, et al, &quot;Prednisolone Excretion in Human Milk,&quot; <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28101605\"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts I, Yates D, Sandercock P, et al, &ldquo;Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial,&rdquo; <i>Lancet</i>, 2004, 364(9442):1321-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/15474134/pubmed\" target=\"_blank\" id=\"15474134\">15474134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi 10.1089/thy.2016.0229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo; <i>Ann Surg</i>, 1994, 219(4):416-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/8161268/pubmed\" target=\"_blank\" id=\"8161268\">8161268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2011;77(24):2128-2134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/22156988/pubmed\" target=\"_blank\" id=\"22156988\">22156988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman DI, Palmert MR, Kemp SF; Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. <i>Pediatrics</i>. 2007;119(2):e484-e494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/17242136/pubmed\" target=\"_blank\" id=\"17242136\">17242136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solu-Cortef preservative free (hydrocortisone sodium) [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2010;95(9):4133-4160. doi: 10.1210/jc.2009-2631<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/20823466/pubmed\" target=\"_blank\" id=\"20823466\">20823466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):111-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/18184957/pubmed\" target=\"_blank\" id=\"18184957\">18184957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Technical Report: Congenital Adrenal Hyperplasia,&rdquo; American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, <i>Pediatrics</i>, 2000, 106(6):1511-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The COIITSS Study Investigators, &ldquo;Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults,&rdquo; <i>JAMA</i>, 2010, 303(4):341-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/20103758/pubmed\" target=\"_blank\" id=\"20103758\">20103758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber-Carstens S, Deja M, Bercker S, et al. Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. <i>Intensive Care Med</i>. 2007;33(4):730-733.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocortisone-systemic-drug-information/abstract-text/17325831 /pubmed\" target=\"_blank\" id=\"17325831 \">17325831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9144 Version 219.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8116174\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8116175\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8116204\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8116314\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8116312\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8116315\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15897565\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897566\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8116380\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8116180\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8116346\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8116215\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726023\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8116164\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8116246\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8116223\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8116244\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8116271\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8116272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8116218\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8116219\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8116222\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8116345\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8116350\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8116300\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8116303\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8116382\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961979\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9144|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydrocortisone-systemic-patient-drug-information\" class=\"drug drug_patient\">Hydrocortisone (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=hydrocortisone-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Hydrocortisone (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}